Interferon-ฮฑ-2a with or without 13-cis r
โ
Sophie D. Fossรฅ; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas;
๐
Article
๐
2004
๐
John Wiley and Sons
๐
English
โ 130 KB
## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin